Clinical trial
Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma
NCT00276692 · Children's Cancer and Leukaemia Group, Other · Completed
Key facts
| NCT number | NCT00276692 |
|---|---|
| Title | Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma |
| Official title | Phase II Study of Irinotecan (CPT-11) in Children and Adolescents With High Risk Ewing's Sarcoma |
| Lead sponsor | Children's Cancer and Leukaemia Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride |
| Enrollment | 35 |
| Start date | Aug 1, 2003 |
| Primary completion | Sep 1, 2008 |
| Completion | Jul 1, 2009 |
| First posted | Jan 13, 2006 |
| Last update posted | Jun 26, 2013 |
| Countries | Ireland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: